JNF is offering three projects to choose from or let JNF decide


 


Eitanim Hospital

Eitanim has an outpatient clinic and a 330-bed facility for the treatment of long-term patients. Although the hospital is surrounded by the verdant hills of Jerusalem, the patients of its three closed wards cannot fully benefit from the beautiful view. The grounds of the facility are neglected and walled-in and its inner courtyard is cramped and uninviting.

To rectify this situation, KKL-JNF is planning a comprehensive landscape development project which will significantly improve the environs as well as double the area of space for patients and staff. Each space will be specifically designed for the use and benefit of the respective patients, promoting well-being and health.

 


ALEH Negev-Nahalat Eran
Neuro-Orthopedic Rehabilitation Hospital

ALEH Negev-Nahalat Eran is a rehabilitative village in Israel’s Negev offering a warm home, loving family and rehabilitation lifeline for hundreds of Israel’s most vulnerable citizens –children, adolescents and adults with severe complex disabilities and accompanying medical conditions.

At the same time, ALEH Negev is committed to providing a comprehensive rehabilitative solution to all residents in the Negev region, where there is no rehabilitation hospital. ALEH Negev is in the midst of construction of a 108-bed faciliity that will provide care in a venue close to home.

 


The MIGAL Galilee Research Institute

The MIGAL Galilee Research Institute Ltd is a regional Research and Development center of the Israeli Science and Technology Ministry, owned by the Galilee Development Company ltd.

An internationally-recognized and multi-disciplinary applied research institute, MIGAL specializes in biotechnology and computational sciences, plant science, precision agriculture and environmental sciences as well as food, nutrition and health.

MIGAL is on the leading edge of developing a COVID-19 vaccine. Because their vaccine does not include the virus itself, it will be safe to use in immune-suppressed recipients and has fewer chances of side effects. JNF is raising funds to bolster this most important work.